Company / Cash & Equivalents
Dyne Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$435.4M
FY2024
5-year range
$121.6M / $435.4M
FY2020-FY2024
Trend
+258.0%
vs FY2023
Sector context
#48 of 209
Health Care
What the data says
Cash & Equivalents changed +258% YoY in FY2024, a notable deviation from the 5-year average annual change of +427%.
Based on SEC 10-K filings.
$435M in FY2024 with a 5-year CAGR of +97.1%. Top quartile in the Health Care sector.
Improved from $172M to $435M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +29.4%
- 5-Year CAGR
- +97.1%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 209This company $435.4M Sector average $696.0M
▼
-37.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +97.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 258.0% year-over-year.
- Ranks #48 out of 209 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $435.4M | +258.0% |
| FY2023 | $121.6M | -29.3% |
| FY2022 | $172.1M | -14.3% |
| FY2021 | $200.8M | -33.2% |
| FY2020 | $300.9M | +1956.1% |
| FY2019 | $14.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026